Q-omics provides the consensus-scored EIF2S2P5 profile across patient tissues and cancer cell-line models. EIF2S2P5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, EIF2S2P5 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, EIF2S2P5 RNA expression shows 7,366 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, STAD, and GBM as cancer lineages where EIF2S2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF2S2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF2S2P5 survival associations across molecular data types. EIF2S2P5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF2S2P5 RNA expression–survival associations across cancer types. High EIF2S2P5 expression shows unfavorable associations in UVM, THCA, TGCT and KICH, but favorable associations in LUAD and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for EIF2S2P5 RNA expression.
This table summarizes EIF2S2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF2S2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF2S2P5 shows higher tumor expression in STAD, COAD and KIRC. The STAD box plot shows higher EIF2S2P5 RNA expression in tumor versus normal tissue (log2 FC = +0.116, t-test p < 0.001).
This table shows molecular features associated with EIF2S2P5 in patient tissues and cancer cell lines. In patient samples, EIF2S2P5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
